RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Sickle Cell Disease
Interventions
PROCEDURE

Haploidentical stem cell transplantation

Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.

OTHER

Standard medical care

Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.

Trial Locations (1)

Unknown

RECRUITING

King's College Hospital, London

All Listed Sponsors
collaborator

King's College London

OTHER

collaborator

University of Sheffield

OTHER

collaborator

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER

collaborator

Imperial College Healthcare NHS Trust

OTHER

collaborator

Guy's and St Thomas' NHS Foundation Trust

OTHER

collaborator

University College London Hospitals

OTHER

collaborator

Manchester University NHS Foundation Trust

OTHER_GOV

collaborator

St George's University Hospitals NHS Foundation Trust

OTHER

collaborator

Barts & The London NHS Trust

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

King's College Hospital NHS Trust

OTHER